1. Home
  2. BDSX vs RENE Comparison

BDSX vs RENE Comparison

Compare BDSX & RENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDSX
  • RENE
  • Stock Information
  • Founded
  • BDSX 2005
  • RENE 2021
  • Country
  • BDSX United States
  • RENE United States
  • Employees
  • BDSX N/A
  • RENE N/A
  • Industry
  • BDSX Precision Instruments
  • RENE Blank Checks
  • Sector
  • BDSX Health Care
  • RENE Finance
  • Exchange
  • BDSX Nasdaq
  • RENE Nasdaq
  • Market Cap
  • BDSX 257.0M
  • RENE 243.8M
  • IPO Year
  • BDSX 2020
  • RENE 2022
  • Fundamental
  • Price
  • BDSX $1.69
  • RENE $11.47
  • Analyst Decision
  • BDSX Strong Buy
  • RENE
  • Analyst Count
  • BDSX 4
  • RENE 0
  • Target Price
  • BDSX $3.08
  • RENE N/A
  • AVG Volume (30 Days)
  • BDSX 238.2K
  • RENE 51.5K
  • Earning Date
  • BDSX 11-05-2024
  • RENE 01-01-0001
  • Dividend Yield
  • BDSX N/A
  • RENE N/A
  • EPS Growth
  • BDSX N/A
  • RENE N/A
  • EPS
  • BDSX N/A
  • RENE 0.36
  • Revenue
  • BDSX $60,902,000.00
  • RENE N/A
  • Revenue This Year
  • BDSX $48.06
  • RENE N/A
  • Revenue Next Year
  • BDSX $29.97
  • RENE N/A
  • P/E Ratio
  • BDSX N/A
  • RENE $31.98
  • Revenue Growth
  • BDSX 46.25
  • RENE N/A
  • 52 Week Low
  • BDSX $1.15
  • RENE $10.80
  • 52 Week High
  • BDSX $2.21
  • RENE $11.58
  • Technical
  • Relative Strength Index (RSI)
  • BDSX 44.40
  • RENE 78.28
  • Support Level
  • BDSX $1.66
  • RENE $11.40
  • Resistance Level
  • BDSX $1.80
  • RENE $11.48
  • Average True Range (ATR)
  • BDSX 0.08
  • RENE 0.01
  • MACD
  • BDSX -0.01
  • RENE -0.00
  • Stochastic Oscillator
  • BDSX 38.46
  • RENE 80.00

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About RENE Cartesian Growth Corporation II

Cartesian Growth Corp II is a blank check company.

Share on Social Networks: